Compliance Certificates under Regulation 74(5) of SEBI (DP) Regulation, 2018

NATCOPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+4.4%1-day move

₹1080.00

prior close

₹1103.80

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.0+0.2+0.3-0.0+4.4+2.2+0.1+1.1+0.4+1.9+1.2+8.8-19.4-10.5

Up moveDown movePending

AI summary

Natco Pharma has submitted a compliance certificate for the quarter ended March 31, 2026, confirming that securities received for dematerialization have been properly processed. The certificate from Venture Capital and Corporate Investments Private Limited (Registrar and Transfer Agent) verifies that share dematerialization requests were handled correctly, with updated records in both NSDL and CDSL depositories within the required 15-day timeframe. The filing includes ISIN: INE987B01026 and covers the Q4 FY2026 period. This is a routine regulatory requirement under SEBI regulations for listed companies.

Likely market impact

This is a standard regulatory compliance filing with no direct impact on the company's financials or stock price. It simply confirms proper processing of share dematerialization requests during the quarter.